Related Experiment Videos
[Rationale for Herceptin in the clinical use]
Hiromichi Ebi1, Yasutsuna Sasaki
1Division of Hematology/Oncology, National Cancer Center Hospital East.
Abstract:
The human epidermal growth factor receptor-2(HER2) is overexpressed/amplified in a number of cancers. HER2 is implicated in disease initiation and progression and associated with poor prognosis. Trastuzumab(Herceptin) is a recombinant DNA-derived humanized anti-HER2 monoclonal antibody that selectively binds with high affinity to extra-cellular domain. In vitro assay, trastuzumab has been shown to inhibit the proliferation of human tumor cells that overexpressed HER2 and to be a mediator of antibody-dependent cellular toxicity. Clinical trials have demonstrated that it is effective as both single and combination with chemotherapeutic agent in recurrent and metastatic breast cancer patients who's tumor tissue are overexpressed HER2. The incidence of severe adverse events were low but the occurrence of cardiac toxicity was unexpectedly high if trastuzumab was combined with anthracycline containing chemotherapy. The further studies are underway to assess the role of trastuzumab in combination chemotherapy, adjuvant chemotherapy and other type of tumors.
Insights
Human epidermal growth factor receptor-2 (HER2) targeted therapy, trastuzumab, shows efficacy in HER2-overexpressing cancers. Combination with anthracyclines increases cardiac toxicity risk, warranting further investigation.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Context:
- Human epidermal growth factor receptor-2 (HER2) overexpression is prevalent in various cancers, correlating with aggressive disease and poor prognosis.
- Trastuzumab is a humanized monoclonal antibody targeting the extracellular domain of HER2.
- HER2 amplification drives tumor growth and is a validated therapeutic target.
Purpose:
- To evaluate the efficacy and safety of trastuzumab in HER2-overexpressing cancers.
- To assess trastuzumab's role as a single agent and in combination chemotherapy.
- To investigate potential toxicities associated with trastuzumab-based regimens.
Summary:
- Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells in vitro and mediates antibody-dependent cellular toxicity.
- Clinical trials confirm trastuzumab's effectiveness in recurrent/metastatic breast cancer with HER2 overexpression.
- Combination therapy with anthracyclines revealed a high incidence of cardiac toxicity.
Impact:
- Trastuzumab represents a significant advancement in targeted therapy for HER2-positive cancers.
- Identifies a critical safety concern regarding cardiotoxicity when combined with anthracyclines.
- Highlights the need for ongoing research into optimal combination strategies and expanded indications for trastuzumab.